Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 9/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.53 |
| ▸ | TUBB | P07437 | 6/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037530 | 0.88 | LMNA (0.64) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL5037713 | 0.86 | LCK (0.56) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL11402160 | 0.85 | TUBB4A (0.60) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL5345714 | 0.85 | LMNA (0.65) | LMNASMN1; SMN2ALDH1A1TUBB4ATUBB | |
| SCHEMBL5351438 | 0.84 | LMNA (0.53) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL31265132 | 0.84 | TUBB4A (0.61) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL11087273 | 0.84 | LMNA (0.53) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL11171719 | 0.84 | NPC1 (0.55) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL11873285 | 0.84 | KDR (0.56) | LMNACYP1A2HIF1ASMN1; SMN2KDR | |
| SCHEMBL4637243 | 0.83 | NPC1 (0.48) | LMNASMN1; SMN2ALDH1A1TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| EP-1432417-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028721-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA S.A. (FR) | 2003-04-10 | — | — | WO | disclosed |
| US-4639463-A | Substituted phenylsulfonyloxybenzimidazolecarbamates and anthelmintic compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | LMNA 4225/4885CYP1A2 734/4885HIF1A 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.